

In the claims:

Claims 1-28 Cancelled

29. (currently amended) A method for delivery of a pharmaceutical composition to gastrointestinal or genitourinary cells to treat or prevent a pathologic condition which comprises contacting the intended site of delivery of said pharmaceutical composition with an agent adequate to cause a temporary disruption of the mucosal lining covering said gastrointestinal or genitourinary cells; and

(b) concurrently or subsequent to said contacting of step (a), contacting said gastrointestinal or genitourinary cells with said pharmaceutical composition, wherein said pharmaceutical composition comprises an adenoviral vector comprising a nucleic acid encoding an antigen derived by HSV-2; whereby expression of said antigen induces an immune response in said recipient specific to said antigen, and wherein said method vaccinates said recipient such that the onset of infection by HSV-2 is inhibited or prevented upon challenge to recipient by HSV-2.

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)